Behçet's disease (BD) is a systemic vasculitis whose prevalence varies according to the ethnicity. HLA-B*51 is a well-known genetic factor predisposing to BD: populations with higher HLA-B*51 allelic frequencies are also those with a greater disease prevalence, as occurs in the Silk Road countries. However, the BD prevalence is unknown in many countries, including Kazakhstan and, in general, Central Asia, despite the location on or near the Silk Road. Due to the lack of clinical studies from this area, we analyzed the bone marrow donors registry in Kazakhstan, in order to assess the HLA-B*51 allelic and carrier frequencies, which resulted to be 8.14 and 15.28%, respectively. Through a comparison with the same parameters in other countries (by performing a data search in the medical literature and in the Allele Frequency Net Database), we might speculate a BD prevalence in Kazakhstan of 10-15/100.000 at least. This result should prompt a greater clinical consideration of this disease in Central Asia, as well as the publication of clinical data from this geographic area.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11739-020-02369-1DOI Listing

Publication Analysis

Top Keywords

hla-b*51 allelic
12
central asia
12
allelic carrier
8
behçet's disease
8
disease prevalence
8
silk road
8
prevalence
5
hla-b*51
4
carrier frequency
4
kazakhstan
4

Similar Publications

Behçet's Disease (BD) is a multisystem inflammatory disorder that can lead to severe vascular complications, including Budd-Chiari Syndrome (BCS), a rare but life-threatening condition characterized by hepatic vein obstruction. The co-occurrence of BD and inherited thrombophilia, such as Factor V Leiden mutation, significantly increases the risk of thrombosis, complicating the clinical management of affected individuals. In this case, a 16-year-old female initially presented with nonspecific symptoms of generalized fatigue and bone pain, which later progressed to abdominal distension and significant hepatosplenomegaly.

View Article and Find Full Text PDF

HLA-B*51:409N differs from the HLA-B*51:01:01:01 by one nucleotide at position 923 in exon 3.

View Article and Find Full Text PDF

HLA-B*51:377N differs from HLA-B*51:01:01:01 in codon 13 in exon 2.

View Article and Find Full Text PDF

HLA-B*51:01 in Iranian patients with Behcet uveitis syndrome.

Reumatol Clin (Engl Ed)

November 2024

Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:

Background: Behcet's disease (BD) is a multisystem disorder prevalent along the historic Silk Road, with Behcet's uveitis (BU) representing a significant complication contributing to disability. Various studies have linked different HLA alleles with BD across diverse populations.

Methods: In this study, we investigated the association between HLA-B51:01/x and HLA-B27/x genotypes with Behcet's uveitis in 50 unrelated Iranian patients diagnosed with Behcet's uveitis, comparing them to a control group of 70 healthy individuals.

View Article and Find Full Text PDF

Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced Hypersensitivity.

J Allergy Clin Immunol Pract

January 2025

Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei, and Keelung, Taiwan; Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan; Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China; Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan; Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou, Taiwan; Department of Dermatology, Beijing Tsinghua Chang Gung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China; Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao-tong University, Shanghai, China; Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan. Electronic address:

Article Synopsis
  • - Osimertinib is an effective lung cancer drug, but it can cause severe allergic reactions, especially in Asian patients, which can complicate treatment.
  • - A study of 17 patients showed that the genetic marker HLA-B*51:02 was found in a high percentage of those experiencing severe allergic reactions (SJS/TEN), indicating a strong genetic predisposition.
  • - The presence of HLA-B*51:02 also correlated with higher levels of a specific protein related to these reactions, suggesting that individuals with this genetic marker may be at risk for severe side effects when taking osimertinib.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!